Tianyin Pharmaceutical Co., Inc. to Host Third Fiscal Quarter 2010 Results Earnings Conference Call on Wednesday, May 12, 2010 at 9:00 a.m. ET

CHENGDU, China, May 7 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a biopharmaceutical company that develops, manufactures and sells modernized traditional Chinese medicine ("TCM") and branded generics based in Chengdu, China, today announced that the senior management will host a conference call to discuss its fiscal 2010 third quarter results at 9:00 a.m. ET on Wednesday, May 12, 2010.

Interested parties may access the call by dialing [phone] (U.S.), or [phone] (International). The conference ID is 4297414. It is advisable to dial in approximately 5-10 minutes prior to the start of the call.

A replay will be available through May 26, 2010 and can be accessed by dialing [phone] (U.S.), or [phone] (International), passcode 4297414.

This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://viavid.net/dce.aspx?sid=00007515

This event is optimized for Microsoft's Windows media player version 9. To download, please go to http://www.microsoft.com/windows/windowsmedia/download .

About Tianyin Pharmaceutical

Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, Sichuan Province of China, is a leading biopharmaceutical company that specializes in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and branded generics. Tianyin is equipped with two state-of-the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. Tianyin currently manufactures and markets a comprehensive portfolio of 50 products, of which 23 are listed in the highly selective National Medicine Catalog of the National Medical Insurance program, 7 are included in the essential drug list of China. Tianyin achieved 10 new drug approvals at SFDA in 2009 and has a pipeline of 12 products pending regulatory approval that target various indications with considerable market potential. Tianyin has an extensive nationwide distribution network with a sales force of 720 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com/ .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact: Tianyin Pharmaceutical Co., Inc. James Jiayuan Tong M.D. Ph.D. Chief Financial Officer, Chief Business & Development Officer Director Add: 23rd Floor Unionsun Yangkuo Plaza No. 2, Block 3, South Renmin Road Chengdu, 610041 China Web: http://www.tianyinpharma.com/ Email: [e-mail] Tel: [phone] (Chengdu, China) [phone] (U.S.)

Tianyin Pharmaceutical Co., Inc.

CONTACT: Investors Contact: James Jiayuan Tong M.D. Ph.D., Chief
Financial Officer, Chief Business & Development Officer, Director, Tianyin
Pharmaceutical Co., Inc. at [e-mail], [phone] or
[phone] (U.S.)

Web site: http://www.tianyinpharma.com/
http://viavid.net/dce.aspx?sid=00007515